Piper Sandler reiterated Overweight rating on AMD with $195 price target. Analyst highlights MI300's strong price-to-performance ratio and server business growth. AMD stock gained 86% in last 12 months.
Mizuho analyst reiterates Buy rating and $230 price target for Amazon (AMZN) based on positive survey results, accelerated sales cycle, and increased AWS spending.
HubSpot shares rise on reports of potential acquisition offer from Alphabet. Analysts maintain overweight rating with $675 price target and see potential for consolidation in SaaS industry. HubSpot has 205K paid customers and 4.9% market share in CRM market.
Analyst maintains Intel with Neutral rating and $42 price target, noting improved laptop CPU share due to Meteor Lake and Raptor Lake refresh, while AMD lacks new CPU. Intel also gained desktop CPU share, and aftermarket retail GPU prices increased. Intel aims for 60% gross margin and 40% operating margin, while Foundry targets 40% gross margin and 30% operating margin long-term, with near-term operating margin at -37%. Focus is on product roadmap execution and margin improvement in Foundry business.
Update on MacroGenics Inc's Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo) for metastatic castration-resistant prostate cancer (mCRPC). Safety and preliminary efficacy data anticipated by May 31. JMP Securities notes enhanced safety profile with new dosing regimen.